Biolipox Interim Report, January - September 2006

* Revenues for the first nine months amounted to SEK 32.6 million (0). For the third quarter revenues amounted to SEK 10.6 million (0).

* Earnings after tax for the first nine months amounted to SEK -49.2 million (-77.9). For the third quarter earnings after tax amounted to SEK -15.7 million (-24.6).

* Earnings per share for the first nine months was SEK -70.12 (-97.77). For the third quarter earnings per share was SEK -22.77 (-31.44).

* Cash flow for the first nine months was negative and amounted to SEK -8.8 million (68.5). For the third quarter cash flow was negative and amounted to SEK -12.4 million (-21.0).

* Drug development projects advance according to plan.

* Biolipox strengthens the R&D organization.


Forthcoming financial information
* Year-end report, 2006 20 February 2007
* Interim report, January - March 2007 10 May 2007
* Interim report, January - June 2007 29 August 2007
* Interim report, January - September 2007 18 October 2007

Biolipox’s interim report 1 January - 30 September, 2006 is presented on the following pages.